Literature DB >> 21376262

A280V polymorphism in the histamine H3 receptor as a risk factor for migraine.

Rebeca O Millán-Guerrero1, Luz M Baltazar-Rodríguez, Martha I Cárdenas-Rojas, Mario Ramírez-Flores, Sara Isais-Millán, Ivan Delgado-Enciso, Ramiro Caballero-Hoyos, Benjamín Trujillo-Hernández.   

Abstract

BACKGROUND AND AIMS: Activation of histamine H3 receptors blocks the release of peptides responsible for headache. Our objective was to investigate the association between the genotypes of A280V polymorphism in the H3 receptor and migraine risk.
METHODS: We evaluated the frequency of the genotypes of A280V, polymorphism A280V and allelic variants of H3 receptor in 147 migraine patients and 186 healthy controls using a PCR-RLFP method.
RESULTS: V allele frequency was 6.46% and 2.68% for the cases and controls, respectively (p = 0.02) (OR 2.67; 95% CI 1.20-5.93). The frequency of V/V + V/A genotypes was 12.92% in migraine patients, significantly higher when compared to the 3.22% frequency in the control group (p = 0.001) (OR 4.45; 95% CI 1.7-11.46).
CONCLUSIONS: The results of this study suggest that V-allele genotypes in the H3 receptor gene are related to migraine risk in the Mexican population. We propose the hypothesis that the V-allele genotypes in the H3 receptor gene increase the population of inactive receptors, enhancing the inhibition of the negative feedback mechanism on the H3 receptor and increasing histamine release, which correlates with migraine attacks in susceptible patients. The case-control study reinforces the role of histamine in migraine pathogenesis.
Copyright © 2011 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21376262     DOI: 10.1016/j.arcmed.2011.01.009

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  7 in total

Review 1.  Migraine signaling pathways: amino acid metabolites that regulate migraine and predispose migraineurs to headache.

Authors:  Roger Gregory Biringer
Journal:  Mol Cell Biochem       Date:  2022-04-28       Impact factor: 3.842

2.  A single-point mutation (Ala280Val) in the third intracellular loop alters the signalling properties of the human histamine H₃ receptor stably expressed in CHO-K1 cells.

Authors:  Cecilia Flores-Clemente; Angélica Osorio-Espinoza; Juan Escamilla-Sánchez; Rob Leurs; Juan-Manuel Arias; José-Antonio Arias-Montaño
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

3.  Associations of Polymorphisms in HRH2, HRH3, DAO, and HNMT Genes with Risk of Chronic Heart Failure.

Authors:  Gong-Hao He; Wen-Ke Cai; Jia-Bin Zhang; Chao-Yu Ma; Feng Yan; Jun Lu; Gui-Li Xu
Journal:  Biomed Res Int       Date:  2016-02-17       Impact factor: 3.411

4.  Migraine Susceptibility Genes in Han Chinese of Fujian Province.

Authors:  Qi Fang Lin; Zi Chun Chen; Xian Guo Fu; Jing Yang; Luo Yuan Cao; Long Teng Yao; Yong Tong Xin; Gen Bin Huang
Journal:  J Clin Neurol       Date:  2017-01       Impact factor: 3.077

5.  Analysis of Missense Variants in the Human Histamine Receptor Family Reveals Increased Constitutive Activity of E4106.30×30K Variant in the Histamine H1 Receptor.

Authors:  Xiaoyuan Ma; Marta Arimont Segura; Barbara Zarzycka; Henry F Vischer; Rob Leurs
Journal:  Int J Mol Sci       Date:  2021-04-02       Impact factor: 5.923

6.  Histamine H(3) receptor integrates peripheral inflammatory signals in the neurogenic control of immune responses and autoimmune disease susceptibility.

Authors:  Dimitry N Krementsov; Emma H Wall; Rebecca A Martin; Meenakumari Subramanian; Rajkumar Noubade; Roxana Del Rio; Gary M Mawe; Jeffrey P Bond; Matthew E Poynter; Elizabeth P Blankenhorn; Cory Teuscher
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

7.  Association of genetic loci for migraine susceptibility in the she people of China.

Authors:  Qi-Fang Lin; Xian-Guo Fu; Long-Teng Yao; Jing Yang; Luo-Yuan Cao; Yong-Tong Xin; Jun-Xia Hou; Lin-Feng Ye; Gen-Bin Huang
Journal:  J Headache Pain       Date:  2015-08-01       Impact factor: 7.277

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.